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a  b  s  t  r  a  c  t
Volunteer  challenge  with  enterotoxigenic  Escherichia  coli (ETEC)  has  been  used  for  four  decades  to eluci-
date the  pathogenesis  and  immune  responses  and  assess  efficacy  of  various  interventions.  We  performed
a  systematic  review  of  these  studies  and  a meta-analysis  of  individual  patient-level  data  (IPD)  from  a
subset  of studies  using  standard  methodology.
We identified  27  studies  of  11  ETEC  strains  administered  to 443  naive  subjects  at  doses  from  1 ×  106 to
1  ×  1010 colony  forming  units  (cfu).  Diarrhea  attack  rates  varied  by strain,  dose  and  enterotoxin.  Similar
rates  were  seen  at doses  of 5 ×  108 to 1 × 1010 cfu with  the  three  most  commonly  used  strains  B7A,
E24377A,  H10407.  In IPD  analysis,  the  highest  diarrhea  attack  rates  were  seen  with  strains  B7A,  H10407
and  E24377A.  The  H10407  induced  significantly  higher  stool  output  than  the other  strains.  Additionally,
the  rate  of  output  was  different  across  strains.
The  risk  of  diarrhea,  abdominal  cramps,  nausea  and  headaches  differed  significantly  by  ETEC  strain.  An
increased  risk  of  nausea,  abdominal  cramps  and  headaches  was  seen  for females.  Baseline  anti-LT  IgG
titers appeared  to be associated  with  a  decrease  risk  of  diarrhea  outcomes,  a  trend  not  seen  with  anti-LT
IgA or  seen  consistently  with  anti-colonization  factor  antibodies.  Neither  early  antibiotic  treatment  nor
diarrhea duration  significantly  affected  the  frequency  or magnitude  of serologic  responses.
These  studies  have  served  as  an  invaluable  tool  in  understanding  disease  course,  pathogenicity,  innate
immune  responses  and  an  early  assessment  of  product  efficacy.  When  designing  and  planning  exper-
imental  ETEC  infection  studies  in  this  age  of  increased  ethical  scrutiny  and  growing  appreciation  of
post-infectious  sequelae,  better  understanding  of  available  data  is essential.
Published by Elsevier Ltd.
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1. Introduction
Over the past 40 years, the enterotoxigenic E. coli (ETEC) human
challenge model has been used to elucidate the pathogenesis and
immune responses associated with ETEC infection as well as to
test the efficacy of investigational drugs and vaccines. The initial
experimental infection, published in 1971, was a landmark study
establishing ETEC as the organism responsible for causing acute,
cholera-like illness in a U.S. soldier in Vietnam [1].  In this classic
paper, researchers demonstrated that while porcine and human
isolates of disease-causing E. coli were both capable of inducing
fluid excretion in rabbit ileal loops, only human isolates were
capable of causing disease in human subjects. It was  later discov-
ered that the difference in the two strains was the species-specific
tropism of the intestinal colonization factor fimbriae.
Since this Landmark publication, ETEC has been established as
the most common cause of diarrhea in travelers as well as in young
children in resource-limited regions of the world. As such, it has
also become the focus of vaccine development efforts [2,3]. Since an
immune correlate of protection has yet to be established and phys-
iologically relevant animal models are lacking, researchers have
frequently relied on the use of vaccine-challenge studies in the early
clinical development of investigational products. This mechanism
has been supportive for vaccine development efforts for cholera,
an enteric pathogen with similar disease mechanisms [4] as well
as other non-enteric pathogens [5]. The basic concept of the ETEC
challenge study is to select a well-characterized, antibiotic suscep-
tible organism that has been associated with diarrhea and related
gastrointestinal symptoms. Under close inpatient supervision, the
strain is fed to volunteers at a dose that induces diarrhea. Illness
is often curtailed by early antibiotic treatment. Preliminary protec-
tive efficacy is then calculated by comparing the diarrhea attack
rates in subjects receiving an investigational product with subjects
receiving placebo.
Here, we have performed a systematic review to thoroughly
examine the published literature and other unpublished data
and compiled aggregate information regarding the pathogenic-
ity, virulence, and immune responses observed in experimental
ETEC infections. Our purpose was to understand the relation-
ship between clinical manifestations of infection and ETEC
virulence factors as well as identify potentially important host-
specific factors similarly associated with clinical outcomes. The
expected outcome is a better understanding of experimental
ETEC infections with regards to factors inherent to the CF-
toxin profiles of the ETEC strains tested, and factors external
to the organism that may  affect pathogenicity such as inocu-
lum preparation and administration procedures, variability in
study populations. Our findings can be applied to the design
and interpretation of future studies with previously untested
ETEC strains.
2.  Methods
This study was  a systematic review of the published and
unpublished literature to evaluate specific outcomes in subjects
participating in experimental ETEC infection studies using the
accepted principles of good methodological design [6,7]. The
methodology included the formulation of an analytic framework
with the development of key questions to be answered by sys-
tematic reviews of the scientific literature. For each question,
the systematic review included eligibility criteria for available
evidence, standardized data abstraction, critical appraisal of the
quality of the evidence, analysis of the data (including a deter-
mination of the appropriateness of applying meta-analysis), and
interpretation of the results.
In addition to study-level information, a subset of studies with
known similarities in specific outcomes was identified for the com-
pilation and analysis of individual patient data. In addition to
evaluating factors inconsistently reported in the published liter-
ature, analysis of pooled individual patient-level data (IPD) affords
the opportunity for more detailed analyses while avoiding some
of the potential biases inherent in analyzing summary statistics of
study participants [8].
2.1. Search strategy
A comprehensive retrieval of information was conducted by ini-
tially performing searches of electronic bibliographies including
MEDLINE, EMBASE, CINAHL, and the Cochrane Library. All searches
were limited to human studies and started with the term ETEC
which was then followed by the addition of the following terms:
infection, efficacy, experimental, inpatient and challenge. In addition,
MEDLINE searches were conducted using major medical subject
headings (MeSH) determined from articles known to be eligible.
Additionally, a manual search of the bibliographies of retrieved arti-
cles was  performed. Conference proceedings, book chapters and
technical reports were also reviewed to identify potential studies.
Because this study was not limited to published articles, we  con-
sulted with experts in the field of ETEC research to identify any
previously unidentified eligible studies. Studies had to be com-
pleted and/or otherwise available prior to January 2009 to be
included in this analysis. All articles, publications and abstracts
were reviewed to determine if they met  the eligibility criteria,
assessed by two independent reviewers (CP and PS).
2.2. Inclusion/exclusion criteria
This study was limited to experimental infection studies in
which subjects received live, unattenuated strains of ETEC bacteria
either as part of the development of an experimental chal-
lenge model, for characterization of strain pathogenicity and/or
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immunogenicity or as controls for the evaluation of a vaccine,
prophylaxis or treatment product. Subjects receiving an investi-
gational product prior to, or after ingesting the ETEC inoculum
were not included in the analysis. The search was limited to studies
reported in the English language.
2.3. Data abstraction
Two reviewers (CP and SI) extracted the data using a pre-tested
data extraction form. Bibliographic information, study design
description, study years, geographic location, population character-
istics, primary outcome measures, inoculum and strain information
and other study characteristics necessary to assess the key param-
eters and to evaluate heterogeneity were included. For studies
involving a vaccine or treatment arm, only data from the placebo
control arm were extracted. Abstraction was not blinded to any
study characteristic such as author, journal or year of publication.
Data were entered separately by each of the reviewers into a
Microsoft Access database. Discrepancies in data points were eval-
uated by a third party and resolved by consensus. Results were
tabulated from individual studies.
2.4. Data analysis
Heterogeneity was assessed using a 2 heterogeneity statistic,
and potential sources of heterogeneity were assessed graphically
by Forest plots and non-parametric methods (e.g., Kruskal–Wallis,
Mann–Whitney U-test) to compare differences in incidence
between two or more groups of a given study characteristic. In
the case of parameters where only a few studies were found, a
median and range of estimates were reported. For summary pur-
poses, point estimates and standard 95% confidence intervals were
combined using a random-effects model with methodology devel-
oped by DerSimonian and Laird [9].  As the principle purpose of
this systematic review was to summarize studies reporting diar-
rhea incidence following experimental infection, publication bias
was not assessed; as such, the concern for non-published findings
due to negative studies or disappointing results was considered
minimal.
The independent study characteristics that were evaluated
included strain and quantity of ETEC administered, inoculum
administration procedures and volunteer characteristics. These
were assessed in relation to their effect on multiple outcomes such
as diarrheal attack rates, disease severity, incubation periods, non-
diarrheal symptoms and qualitative immune responses to both the
colonization factor and the toxin (when appropriate).
2.5. Individual patient level data analysis
For the IPD analysis, only studies for which IPD was obtained
were included. Also, these analyses were limited to studies utilizing
the same inoculum administration procedures and outcome defi-
nitions (diarrhea, immune response, etc.). This analysis included
7 separate studies evaluating 12 strain/dose combinations and a
total of 134 subjects. All but one of the studies (evaluating two
doses of two separate ETEC strains) were performed by the same
principal investigator (PI) at the same clinical facility. For that
study, we evaluated the impact of the different clinical site and
PI on the clinical outcomes. The lack of significant differences in
study populations, or clinical or immunologic outcomes for the lone
strain/dose combination in question, led us to combine the data
from the multiple studies as if they were performed as a single clin-
ical trial instead of utilizing multilevel and/or hierarchical models
to allow for adjustment of between-trial variance (deemed of min-
imal impact for this unique dataset) [10,11].  Outcomes evaluated
were the same as those for the over-arching meta-analysis. Post hoc
Fig. 1. Flow diagram for studies included in systematic review.
analyses of non-parametric continuous variables were performed
using a bonferroni-adjusted alpha for pair-wise comparisons.
3. Results
3.1. Meta-analysis
A total of 27 studies were identified for inclusion (Fig. 1). A
thorough review of the published literature identified a total of
22 reports of experimental ETEC infection. However, 4 publica-
tions reported different aspects of only 2 different clinical trials
[12–15], yielding 19 individual studies. One additional study was
identified in two  separate book chapters with topics related to ETEC
vaccine pathogenicity and vaccine development [16,17]. We  also
included 6 unpublished studies for which three principal investiga-
tors have been extensively involved. These included administration
of 7 different ETEC strains (E24377A, H10407, LSN03-016011/A,
WS0115A, DS26-1) in experimental infection or preliminary pro-
tective efficacy studies at the inpatient facilities at Johns Hopkins
University. We  excluded one study that did not report any data on
clinical outcomes following ETEC ingestion [18]. A complete listing
of all included studies is shown in Table 1 .
The majority (70%) of the published studies were printed in a
12-year span between 1977 and 1988. However, the past decade
has seen an increase in the number of experimental ETEC infection
studies, many of which are currently unpublished. Eleven of the
27 studies (41%) performed to date have been to fully define and
understand the experimental human ETEC infection model with
various ETEC strain/dose combinations. The additional studies were
performed to utilize these models to evaluate vaccine candidates
(n = 8), antibiotics (n = 1) or other prophylactic and/or treatment
intervention (n = 7). Variability in the outcomes reported and types
of summary effect estimates utilized was also variable across
studies.
Over the past four decades of experimental ETEC infection stud-
ies, the diarrhea definition has been quite varied. The first definition
utilized by Dupont et al. was “3 watery stools/24-h period” [1].
Subsequently, the diarrhea definition was modified to allow for
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Table  1
List of experimental ETEC infection studies that met  inclusion criteria for systematic review and meta-analysis.
Ref (pub. yr.) Primary
Author or
Investigator
Study
typea
Agar NaHCO3
buffer
Inoc.
solution
Dia.
Def.b
Strain Dose
(cfu)
N N (%)
diarrhea
Comments
[1] (1971) Dupont A TSA No Milk A
B2C
1E8 5 2 (40) 100% colonization; no abx
treatment
1E10 5 3 (60) 100% colonization; no abx
treatment
B7A
1E8 5 1 (20) 80% colonization; no abx
treatment
1E10 5 4 (80) 100% colonization; no abx
treatment
[61]  (1977) Levine A TSA No Milk B 214-4
1E6 4 0 (0) 50% somatic response; 0% LT
response
1E8  5 2 (40) All illnesses lasted 1 day;
median incubation
period = 45 h; 75%
colonized; 80% somatic
response; 0% LT response
1E10 5 4 (80) Median illness duration: 3
days; median incubation
period = 20.8 h; 1 subject
vomited; 100% colonized;
80% somatic response; 0% LT
response
[12,13]  (1978) Evans/SatterwhiteA CFA Yes PBS NR H10407
1E6 7 0 (0) 1 subject with 1 LLS,
anorexia, nausea and severe
abdominal pain; 50%
serocon to CFA/I
(GMT = 6.5); 33% serocon to
LT (GMT = 29)
1E8 7 6 (86) Mean # LLS: 9.2; 3 subjects
with abdominal pain, 2 with
vomiting; 67% serocon to
CFA/I (GMT = 17.9); 43%
serocon to LT (GMT = 39.0)
[62]  (1979) Levine A TSA Yes PBS B
B7A
1E6 6 3 (50) 100% colonization; 1 (17%)
with fever; 33% serocon to
LT and somatic antigens; all
3  subjects with diarrhea
protected from homologous
re-chall at 1 × 108
1E8 11 7 (64) 100% colonization; 2 (18%)
with fever; 89% serocon to
LT and somatic antigens; 6
of  7 (86%) with diarrhea
protected from diarrhea
upon homologous re-chall
at 1 × 108
1E8 12 7 (58) Mean incubation: 45 h;
mean volume: 0.9 L; mean #
LLS: 4.7; 2 (17%) with
nausea/vomiting; 7 (58%)
with malaise; 92% serocon
to  LT and 83% to somatic
antigens; 1 of 4 (25%) with
diarrhea protected from
diarrhea upon heterologous
re-chall at 1 × 109 with
E2528-C1
E2528-C1 1E9 6 2 (33) Mean incubation: 16 h;
mean volume: 0.5 L; mean #
LLS: 4.5; 67% serocon to LT
and 33% to somatic antigens
[63]  (1980) Levine A TSA Yes PBS C
H10407 1E8 4 2 (40) 1 subject with nausea and
vomiting but only 1 LLS; 3
(75%) subjects with anorexia
and abdominal cramps; 75%
serocon to LT and 100% to O
antigen
214-4 1E8 4 4 (100) Range of # LLS: 3-19; range
of total volume: 0.5–3.5 L;
100% with abdominal
cramps; 75% with nausea;
100% serocon to O antigen
and 0% to LT
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[64] (1981) Clements D TSA Yes NaHCO3 D
TD225-C4 1E10 5 2 (40) Mean incubation: 9.6 h;
mean #LLS: 3.5; mean total
volume: 0.6 L; mean
duration: 18.0 h; 20% with
fever, 0% vomiting, 80% with
abd. cramps, 40% with
anorexia, 60% with malaise;
100% colonization
214-4 1E8 5 4 (80) Mean incubation: 24.5 h;
mean #LLS: 5.0; mean total
volume: 0.7 L; mean
duration: 30.2 h; 20% with
fever, 0% vomiting, 60% with
abd. cramps, 80% with
anorexia, 80% with malaise;
100% colonization
H10407 1E8 4 3 (75) Mean incubation: 57.5 h;
mean #LLS: 6.7; mean total
volume: 1.3 L; mean
duration: 21.3 h; 25% with
fever, 25% vomiting, 100%
with abd. cramps, 25% with
anorexia, 0% with malaise;
100% colonization
B7A 1E8 3 3 (100) Mean incubation: 23.4 h;
mean #LLS: 4.7; mean total
volume: 0.5 L; mean
duration: 30.2 h; 100%
colonization
1E10 8 5 (63) Mean incubation: 14.4 h;
mean #LLS: 11.8; mean total
volume: 1.5 L; mean
duration: 60.8 h; 100%
colonization
[36]  (1982) Black C CFA Yes NaHCO3 E H10407 5E8–5E9 41 31 (76) After diarrhea onset,
subjects randomized to
treatment (11 to placebo);
For placebo-treated
subjects: mean duration:
82.1 h; mean # LLS: 12.0;
mean volume: 2.2 L; 55%
vomiting, 91% abd cramps
(lasting 3.6 days), 91%
anorexia (lasting 3.2 days);
100% colonization
[65]  (1982) Levine B CFA Yes PBS D
B7A 1E10 6 4 (67) Mean volume: 0.6 L; mean #
LLS: 4.3; 100% colonization
H10407
1E7 11 3 (27) Mean volume: 1.2 L; mean #
LLS: 15.3; 100% colonization
5E8 8 7 (88) Mean volume: 3.0 L; mean #
LLS: 12.3; 100% colonization
5E8 7 7 (100) Mean volume: 4.0 L; mean #
LLS: 18.0; 100% malaise and
86% vomited; 2 (29%)
required IV fluids; 100%
colonization
[14,15] (1983) Graham D CFA Yes PBS C H10407 2.7E8 16 9 (56) Initial phase included 32
subjects randomized to
prophylaxis with bismuth
subsalicylate (n = 16) or
placebo (n = 16). After
diarrhea onset, subjects
randomized to treatment
with bismuth subsalicylate
(n = 6) or placebo (n = 5). For
the 5 placebo recipients:
mean # LLS over 48 h: 7.0;
80% nausea, 40% vomiting,
100% abd cramps, 40%
headache, 60% fever
[66]  (1984) Evans B CFA Yes PBS NR
H10407 4E8 5 2 (40) No data on additional
ETEC-associated symptoms
provided
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H1765 4E8 6 5 (83) No data on additional
ETEC-associated symptoms
provided
[67]  (1984) Levine A TSA Yes PBS NR E24377A 5E8 14 9 (64) 50% seroconversion to CS1
and 50% to CS3; No data on
additional ETEC-associated
symptoms provided
[16,17] (1986) Levine B NR NR NR NR E24377A 5E8 6 6 (100) Study published in 2 book
chapters; no additional data
provided
[30]  (1988) Evans B CFA Yes PBS F H10407 5E9 5 5 (100) Mean stool weight at peak
of illness: 765 g;
[31]  (1988) Evans B CFA Yes PBS F H10407 5E9 9 8 (89) Mean total weight for 24 h
during peak illness: 900 g;
mean time to 1st LLS:
30.9 h; 88% colonization
[40]  (1988) Tacket D NR Yes NaHCO3 G H10407 1.2E9 10 9 (90) Subjects received NaHCO3
buffer over 2 days prior to
and for 5 days after ETEC
admin as part of
immunoprophylaxis. Mean
diarrhea volume: 1.5 L;
mean diarrhea onset time:
48 h; 80% abdominal
cramps, 60% vomiting, 90%
malaise, 20% fever, 90%
anorexia; 60% received early
abx.; 100% colonization; 40%
seroconversion to CFA/I, 50%
to LT and 100% to O antigen
[68]  (1994) Tacket B NR Yes NaHCO3 NR E24377A 3E9 10 10 (100) Mean volume: 1.5 L; mean #
LLS: 8.6; 90%, 40% and 90%
IGA ASC responses to CFA/II,
CS1 and CS3, respectively
[41]  (1998) Freedman D NR Yes NaHCO3 G H10407 1E9 10 7 (70) Subjects received NaHCO3
buffer over 2 days prior to
and for 5 days after ETEC
admin as part of
immunoprophylaxis. Mean
volume: 1.3 L; mean # LLS:
7.4; 100% abd cramps, 60%
anorexia, 50% headache, 30%
malaise; 100% serologic
response to CFA/I, LPS and LT
[69]  (1999) Tacket D NR No Apple-
sauce
G E24377A 1E8 10 3 (30) Mean volume: 0.8 L; mean #
LLS: 5.3; 100% colonization;
100% seroconversion to LT
and 20% to CS3
[70]  (2007)c Coster A TSA Yes NaHCO3 C
B7A
1.5E9 8 5 (63) Mean weight: 1.0 kg; mean
onset time: 10 h; 25%
mod-sev abd cramps, 25%
mod-sev headache, 13%
mod-sev nausea, 13%
mod-sev loss of appetite, 0%
mod-sev fever; 100%
colonization
1.4E10 8 8 (100) Mean weight: 0.9 kg; mean
onset time: 12 h; 38%
mod-sev abd cramps, 38%
mod-sev headache, 38%
mod-sev nausea, 0%
mod-sev loss of appetite,
25% mod-sev fever; 100%
colonization
H10407
1.2E8 7 6 (86) Mean weight: 1.9 kg; mean
onset time: 43 h; 71%
mod-sev abd cramps, 57%
mod-sev headache, 43%
mod-sev nausea, 71%
mod-sev loss of appetite,
43% mod-sev fever; 100%
colonization
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1.4E9 8 7 (88) Mean weight: 1.9kg; mean
onset time: 34 h; 100%
mod-sev abd cramps, 63%
mod-sev headache, 63%
mod-sev nausea, 75%
mod-sev loss of appetite,
38% mod-sev fever; 100%
colonization
[21]  (2007) McKenzie B CFA Yes NaHCO3 G E24377A 6E8 20 20 (100) Mean weight: 1.1 kg; mean
# LLS: 9.7; 40% received IV
fluids; mean time to
diarrhea onset: 29 h; mean
time to abx: 51 h
2008  [71] McKenzie B CFA Yes NaHCO3 G E24377A 3E9 16 13 (81) Median volume: 0.9 L;
median # LLS: 6; median
max. 24 h, volume: 0.9 L;
median time to diarrhea
onset: 24.1 h; median
duration: 32.2 h; 0% fever,
67% malaise; 73% abdominal
cramps; 47% nausea; 33%
headache; 7% vomiting; 31%
IV fluids; 50% early abx
Unpubc McKenzie A CFA Yes NaHCO3 G H10407 1.1E9 5 5 (100) Median volume: 1.5 L;
median # LLS: 13; median
max. 24 h, volume: 1.0 L;
median time to diarrhea
onset: 25.7 h; median
duration: 46.6 h; 0% fever,
80% malaise; 80% abdominal
cramps; 60% nausea; 80%
headache; 40% vomiting;
20% IV fluids; 100% early abx
Unpubc McKenzie D CFA Yes NaHCO3 G H10407 1E9 11 9 (82) Subjects received NaHCO3
buffer over 2 days prior to
and for 3 days after ETEC
admin as part of
immunoprophylaxis.
Median volume: 1.9 L;
median # LLS: 10; median
max. 24 h, volume: 1.2 L;
median time to diarrhea
onset: 22.8 h; median
duration: 53.8 h; 27% fever,
55% malaise; 73% abdominal
cramps; 36% nausea; 73%
headache; 18% vomiting;
45% IV fluids; 55% early abx
[72] c McKenzie A CFA Yes NaHCO3 G
LSN03-
016011/A
7.0E8 5 3 (60) Median volume: 0.8 L;
median # LLS: 6; median
max. 24 h, volume: 0.6 L;
median time to diarrhea
onset: 11.7 h; median
duration: 27.3 h; 0% fever,
60% malaise; 80% abdominal
cramps; 20% nausea; 20%
headache; 40% vomiting;
20% IV fluids; 60% early abx
6.2E9 8 7 (88) Median volume: 1.0 L;
median # LLS: 6; median
max. 24 h, volume: 0.5 L;
median time to diarrhea
onset: 11.7 h; median
duration h: 10.4; 0% fever,
63% malaise; 75% abdominal
cramps; 25% nausea; 25%
headache; 25% vomiting;
13% IV fluids; 38% early abx
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[72] c McKenzie D CFA Yes NaHCO3 G LSN03-
016011/A
5E9 12 6 (50) Subjects received NaHCO3
buffer over 2 days prior to
and for 5 days after ETEC
admin as part of
immunoprophylaxis.
Median volume: 0.8 L;
median # LLS: 5; median
max. 24 h, volume: 0.5 L;
median time to diarrhea
onset: 21.9 h; median
duration: 34.5 h; 0% fever,
33% malaise; 50% abdominal
cramps; 42% nausea; 33%
headache; 8% vomiting; 0%
IV fluids; 25% early abx
[72] c McKenzie A CFA Yes NaHCO3 G
WS0115A
4E8 5 1 (20) Median volume: 1.2 L;
median # LLS: 5; median
max. 24 h, volume: 1.2 L;
median time to diarrhea
onset: 16.7 h; median
duration: 10.0; 0% fever, 20%
malaise; 40% abdominal
cramps; 20% nausea; 20%
headache; 0% vomiting; 20%
IV fluids; 20% early abx
3E9 6 2 (33) Median volume: 0.7 L;
median # LLS: 6; median
max. 24 h, volume: 0.4 L;
median time to diarrhea
onset: 6.8 h; median
duration: 46.9 h; 0% fever,
50% malaise; 50% abdominal
cramps; 33% nausea; 67%
headache; 0% vomiting; 20%
IV fluids; 0% early abx
9.2E9 9 4 (44) Median volume: 0.7 L;
median # LLS: 5; median
max. 24 h, volume: 0.4 L;
median time to diarrhea
onset: 25.1 h; median
duration: 36.0 h; 0% fever,
22% malaise; 22% abdominal
cramps; 11% nausea; 33%
headache; 0% vomiting; 20%
IV fluids; 0% early abx
DS26-1 4E8 5 0 (0) Only ETEC-associated
symptom was  40%
headache; 0% IV fluids; 0%
early abx
Unpubc McKenzie A CFA Yes NaHCO3 G E24377A 7.3E8 10 8 (80) Median volume: 0.8 L;
median # LLS: 7; median
max. 24 h, volume: 0.6 L;
median time to diarrhea
onset: 50.0 h; median
duration: 47.3 h; 0% fever,
50% malaise; 63% abdominal
cramps; 25% nausea; 13%
headache; 0% vomiting; 10%
IV fluids; 20% early abx
3.1E9 5 4 (80) Median volume: 1.3 L;
median # LLS: 9; median
max. 24 h, volume: 0.9 L;
median time to diarrhea
onset: 22.3 h; median
duration: 53.0 h; 20% fever,
80% malaise; 100%
abdominal cramps; 60%
nausea; 40% headache; 0%
vomiting; 40% IV fluids; 40%
early abx
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4.9E9 5 4 (80) Median volume: 0.7 L;
median # LLS: 7; median
max. 24 h, volume: 0.7 L;
median time to diarrhea
onset: 22.5 h; median
duration: 29.8 h; 0% fever,
40% malaise; 60% abdominal
cramps; 60% nausea; 40%
headache; 20% vomiting;
20% IV fluids; 40% early abx
abx: antibiotic; AR: attack rate; LLS: loose or liquid stools (frequently referred to as grade 3, 4 or 5 stools [19]); mod-sev: moderate to severe; NR: not reported; serocon:
seroconversion; #: number.
a Study types: (A) pathogenesis; (B) vaccine efficacy; (C) antibiotic treatment; (D) other treatment and/or prophylaxis.
b Diarrhea definitions: (A) ≥3 LLS in 24 h.; (B) ≥3 LLS in 24 h or 1 LLS ≥ 200 mL;  (C) ≥2 LLS in 24 h; (D) ≥3 LLS or ≥2 LLS at ≥200 mL  in 48 h or 1 LLS ≥300 mL;  (E) ≥2 LLS; (F)
≥2  LLS + 1 somatic complaint; (G) ≥2 LLS in 48 h at ≥200 mL  or 1 LLS ≥300 mL.
c These studies used ETEC strains for which the seed lots were manufactured under Good Manufacturing Practices.
a volume quantification of either 1 or 2 loose stools over a 24
or 48 h time period. In 1978, Levine et al. established a grading
system for scoring stools which has been subsequently used to
classify loose stools as those coded as grade 3 (“thick liquid”),
4 (“opaque-watery”) or 5 (“rice-water”) [19]. This grading sys-
tem has been consistently utilized since, although the number
and/or quantity of stools required to meet the diarrhea definition
remained inconsistent. The most common diarrhea outcome def-
inition, used in 41% of the studies is ≥200 mL  of Grade 3, 4 or
5 stools within a 48 h period or 1 Grade 3, 4 or 5 stool totaling
≥300 mL.
Eleven different strains have been utilized in these studies and
summary information about each is provided in Table 2. The three
most commonly administered strains are H10407, E24377A and
B7A all three of which express both the LT and ST enterotoxins.
As shown in Fig. 2, the percent of subjects reaching the primary
outcome of diarrhea has varied within and across a range of
dose-strain combinations. The majority of studies (88.5%) involved
volunteer pretreatment with sodium bicarbonate prior to admin-
istration of the challenge inoculum. Most commonly the vehicle to
administer the challenge strain was  also sodium bicarbonate (52%),
although saline (33%), milk (7%) and apple sauce (4%) have also been
used.
When limiting our analyses to the 3 most utilized strains, B7A,
H10407 and E24377A, we found that the diarrhea attack rate
was dose-dependent with increasing doses associated with higher
attack rates (p < 0.01). Interestingly, when evaluating these strains
at doses of 5 × 108 and higher cfu, there was no difference in diar-
rhea attack rates (heterogeneity chi-square p = 0.07) across any of
the strains at doses up to 1 × 1010, with an overall attack rate of 87%
(95% CI 82, 92) and strain-specific attack rates of 78% (95% CI: 64,
92), 89% (95% CI: 79, 98) and 87% (95% CI: 81, 93) for B7A, E24377A
Table 2
Detailed information on strains of ETEC that have used for experimental human infection.
Strain name Initial strain description Serotype CF(s) Toxin(s) Country/region of origin Clinical information on index
case
Range of
doses
administered
214-4 [73] Not typeable Unknown ST Mexico Isolated from 29 year-old
Caucasian male physician with
travelers’ diarrhea
characterized by watery
diarrhea, abdominal cramps,
malaise, nausea and fever
1E6–1E10
B2C  [1] O6:H16 CS2, CS3 LT/ST Vietnam Diarrhea case in US military
adult
1E8
B7A  [1] O148:H28 CS6 LT/ST Vietnam Diarrhea case in US military
adult serving in Vietnam
1E6–1E10
DS26-1 [72] O8:H9 CS19 LT Saudi Arabia Isolated in 1990 from a U.S.
soldier with diarrhea while on
deployment during Operation
Desert Shield
5E8
E24377A [74] O139:H28 CS1, CS3 LT/ST Egypt Traveler returning from Egypt
with ETEC disease
1E8–3E9
E2528-C1 [75] O25:NM Unknown LT Caribbean Cruise ship diarrhea outbreak 1E9
H10407 [76] O78:K80:H11 CFA/I LT/ST Bangladesh Severe case of watery diarrhea 1E6–5E9
H1765  [66] O6:K15:H16 CFA/II LT/ST Bangladesh Unknown 4E8
LSN03-016011/A [72] O8:H- CS17 LT Turkey Isolated from 29 year-old U.S.
female military with acute,
watery diarrhea shortly after
arrival at Incirlik Airbase in
Turkey
5E8–5E9
TD225-C4 [64] O75:H9 Unknown LT Mexico Case of diarrhea 1E10
WS0115A [77]  O114:H- CS19 LT/ST Egypt Isolated from stool of
12-month old Egyptian female
suffering from watery diarrhea
in  Abees, Egypt
5E8–5E10
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Fig. 2. Point estimate and 95% confidence interval for the proportion of subjects
meeting the primary outcome of diarrhea for all included dose and strain combina-
tions. Diamond: point estimate; horizontal line: 95% confidence interval.
and H10407, respectively. The diarrhea attack rates of strains with
similar toxin phenotypes at the ≥5E8 dose showed significant het-
erogeneity, with the highest rates following administration of LT/ST
strains (84%; 95% confidence interval {CI}: 78, 89; heterogeneity
chi-square p = 0.02) followed by ST only strains (80%; 95% CI: 52,
100; no p-value as only 1 study included) and LT only strains (57%;
95% CI: 33, 81; heterogeneity chi-square p = 0.02). For the purposes
of this analysis, we  excluded the DS26-1 strain which did not induce
diarrhea at any of the inoculum doses administered. We  found no
significant effect on diarrhea rates with changing inoculum solu-
tion, agar used for strain growth or fasting time, although our power
was relatively limited to find these effects.
3.2. Individual patient level data
3.2.1. Clinical data
The individual patient-level data is shown in Table 3 and
includes 133 subjects administered 1 of 6 ETEC strains at doses of
1E8 to 1E10. The highest diarrhea attack rates were seen with B7A
at ∼1E10 cfu (100.0%), H10407 at ∼1E9 cfu (87.5%) and E24377A at
∼5E9 cfu (80.8%). Strains expressing CS17 (LSN03-016011/A) and
CS19 (WS0115A) also caused diarrhea, although at lower attack
rates and a strain expressing CS19 (DS26-1) caused no diarrhea.
There was  a higher proportion of severe diarrhea among all doses
of H10407 compared to the other strains. The only dose/strain com-
bination that resulted in a similar proportion of severe diarrhea was
the B7A strain at the 1E10 inoculum.
There were also apparent strain differences in the non-
diarrheal symptoms following ETEC inoculation. While abdominal
cramps/pain, nausea, malaise and headache were relatively com-
mon  across all doses and strains (excluding DS26-1), vomiting
was seen most frequently following inoculation with the strains
H10407, B7A and LSN03-016011/A. Similarly, fever was relatively
infrequent in all strains except H10407 and B7A. While most
strains demonstrated a range of severity in these ETEC-associated
symptoms, the H10407 strain exhibited markedly more severe
symptoms. The need for intravenous fluids (I.V.) was  relatively
rare, possibly due to the high frequency of early antibiotic treat-
ment across dose/strain combinations. Although not shown here,
all subjects were encouraged to consume oral rehydration solution
or other oral fluids at diarrheal onset, potentially decreasing the
need for I.V. fluids.
A more detailed description of the diarrhea episode among
subjects meeting the diarrhea definition is shown in Table 4.
Regardless of dose, H10407 exhibited a significantly higher num-
ber of unformed stools (all p < 0.013 except: B7A {p = 0.014},
E24377A {p = 0.022}), total volume (all p < 0.013) and maximum
24 h volume (all p < 0.013 except: E24377A {p = 0.022}) than the
other strains. The increase in the total number of unformed
stools and total diarrhea may  be explained by the longer dura-
tion of the diarrheal episode seen with both evaluated doses
of the H10407 strain. Interestingly, the time to antibiotic treat-
ment was quite variable across dose/strain combinations, likely
reflecting differences in strain pathogenicity and clinical treatment
algorithms.
The median time to the first loose stool was quite variable, and
ranged from 6.8 to 50.0 h post-inoculation. Fig. 3 shows a detailed
representation of stool volume accumulation and number of stools
for the four strains resulting in the highest diarrhea attack rates.
The volume of loose stools at the highest H10407 dose (1 × 109)
increases at a higher rate than the other strains regardless of dose,
and continues to increase throughout the observation period. In
contrast, the output for the ‘low dose’ (1 × 108) of H10407 is rela-
tively consistent with the other dose/strain combinations until the
72 h timepoint when it increases remarkably. The stool volume and
count for the ‘low dose’ (5 × 108) of strain E24377A falls between
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Table 3
Description of primary outcomes following experimental infection with enterotoxigenic Escherichia coli (ETEC).
Strain H10407 E24377A B7A LSN03-016011/A WS0115A DS26-1
Approximate dose 1E8 1E9 5E8 5E9 1E9 1E10 5E8 5E9 5E8 5E9 1E10 5E8
N 7 24 10 26 8 8 5 20 5 6 9 5
%  male 57.1 58.3 90.0 76.9 87.5 50.0 80.0 60.0 60.0 66.7 88.9 60.0
%  African American 42.9 70.8 80.0 76.9 50.0 37.5 100.0 85.0 100.0 100.0 88.9 100.0
Median  (IQR) age 46.2 (37.4,
49.6)
31.6 (25.4,
40.3)
43.0 (21.0,
47.0)
37.5 (22.0,
43.0)
43.2 (25.6,
51.2)
37.2 (28.1,
43.8)
34.9 (32.9,
35.8)
31.6 (25.1,
41.1)
40.3 (38.6,
44.5)
34.3 (24.8,
41.3)
25.5 (24.0,
31.2)
28.7 (19.8,
30.3)
%  diarrhea 85.7 87.5 70.0 80.8 62.5 100.0 60.0 65.0 20.0 33.3 44.4 0.0
Mild  0 12.5 20.0 19.2 25.0 0.0 20.0 15.0 0.0 0.0 0.0 0.0
Moderate 0 4.2 30.0 23.1 0.0 25.0 0.0 30.0 20.0 33.3 33.3 0.0
Severe  85.7 70.8 20.0 38.5 37.5 75.0 40.0 20.0 0.0 0.0 11.1 0.0
%  abdominal cramps 85.7 83.3 62.5 76.0 62.5 62.5 80.0 60.0 40.0 50.0 22.2 0.0
Mild  14.3 16.7 25.0 28.0 37.5 25.0 0.0 10.0 40.0 0.0 11.1 0.0
Moderate 0 29.2 37.5 24.0 12.5 0.0 20.0 30.0 0.0 50.0 11.1 0.0
Severe  71.4 37.5 0.0 24.0 12.5 37.5 60.0 20.0 0.0 0.0 0.0 0.0
%  Nausea 71.4 50.0 25.0 48.0 37.5 62.5 20.0 35.0 20.0 33.3 11.1 0.0
Mild  28.6 4.2 25.0 24.0 25.0 25.0 0.0 65.0 20.0 16.7 16.7 0.0
Moderate 0 8.3 0.0 12.0 12.5 0.0 0.0 20.0 0.0 0.0 0.0 0.0
Severe  42.9 37.5 0.0 12.0 0.0 37.5 20.0 15.0 0.0 16.7 0.0 0.0
%  Malaise 57.1 62.5 50.0 64.0 0.0 37.5 60.0 45.0 20.0 50.0 22.2 0.0
Mild  0 8.3 12.5 20.0 0.0 12.5 0.0 20.0 20.0 0.0 22.2 0.0
Moderate 14.3 25 25.0 24.0 0.0 12.5 20.0 10.0 0.0 16.7 0.0 0.0
Severe  42.9 29.2 12.5 20.0 0.0 12.5 40.0 15.0 0.0 33.3 0.0 0.0
%  headache 57.1 70.8 12.5 36.0 37.5 87.5 20.0 30.0 20.0 66.7 22.2 40.0
Mild 0  4.2 0.0 16.0 12.5 50.0 0.0 25.0 20.0 16.7 22.2 20.0
Moderate 14.3 4.2 12.5 12.0 12.5 25.0 20.0 5.0 0.0 0.0 0.0 0.0
Severe 42.9 25 0.0 8.0 12.5 12.5 0.0 0.0 0.0 50.0 0.0 20.0
%  vomiting 42.9 33.3 0.0 8.0 0.0 25.0 40.0 15.0 0.0 0.0 0.0 0.0
Mild 0  4.2 0.0 4.0 0.0 12.5 40.0 5.0 0.0 0.0 0.0 0.0
Moderate 14.3 4.2 0.0 0.0 0.0 0.0 0.0 5.0 0.0 0.0 0.0 0.0
Severe  28.6 25 0.0 4.0 0.0 12.5 0.0 5.0 0.0 0.0 0.0 0.0
%  lightheaded 57.1 47.8 25.0 28.0 25.0 25.0 20.0 10.0 0.0 30.0 11.1 0.0
Mild  14.3 13.0 12.5 16.0 25.0 25.0 0.0 10.0 0.0 33.3 11.1 0.0
Moderate 14.3 26.1 0.0 4.0 0.0 0.0 20.0 0.0 0.0 16.7 0.0 0.0
Severe  28.6 8.7 12.5 8.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
%  fever 42.9 25.0 0.0 4.0 12.5 25.0 0.0 0.0 0.0 0.0 0.0 0.0
Mild  28.6 16.7 0.0 4.0 12.5 25.0 0.0 0.0 0.0 0.0 0.0 0.0
Moderate 14.3 4.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Severe  0.0 4.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
%  intravenous fluid 0.0 25.0 10.0 30.7 0 12.5 20.0 5.0 0.0 0.0 0.0 0.0
%  early abx. treatment 85.7 70.8 20.0 46.2 12.5 75.0 60.0 30.0 20.0 0.0 0.0 0.0
%  seroconversion
2-fold
LT IgG 57.1 95.8 100.0 92.3 75.0 62.5 80.0 80.0 80.0 83.3 66.7 40.0
LT  IgA 71.4 91.7 100.0 69.2 87.5 62.5 80.0 65.0 60.0 50.0 55.6 40.0
CF  IgG 100.0 70.8 40.0a 7.7a 37.5 12.5 100.0 100.0 60.0 100.0 88.9 20.0
CF  IgA 100.0 50.0 70.0a 11.5a 50.0 12.5 100.0 95.0 100.0 83.3 100.0 40.0
4-fold
LT  IgG 42.9 83.3 100.0 88.5 37.5 25.5 80.0 75.0 60.0 50.0 44.4 20.0
LT  IgA 42.9 83.3 90.0 65.4 62.5 50.0 80.0 65.0 60.0 50.0 55.6 40.0
CF  IgG 100.0 70.8 40.0 7.7 37.5 12.5 60.0 85.0 40.0 33.3 44.4 0.0
CF  IgA 100.0 50.0 40.0 3.9 50.0 12.5 100.0 85.0 60.0 83.3 100.0 40.0
%  ASC response
LT IgA 85.7 79.2 100.0 76.9 100.0 75.0 ND ND ND ND ND ND
CF  IgA 100.0 37.5 100.0b 96.2b 87.5 12.5 ND ND ND ND ND ND
a Shown are response rates to CS3 (CS1 response rates 1 × 108: IgG = 50.0, IgA = 70.0; 1 × 109: IgG = 69.2, IgA = 65.4).
b Shown are response rates to CS3 (CS1 response rates 1 × 108 = 100.0; 1 × 109 = 92.3).
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Table  4
Description of diarrheal episode {presented as median (interquartile range)} among subjects meeting diarrhea definition by strain and approximate dose.
Strain Approx.
dose
# Loose stools Total volume Time to first loose
stool
Maximum 24 h
volume
Duration Time to antibiotic
treatment
H10407
1E8 8.5 (5.0, 17.0) 1923.0 (1125.0, 2673.0) 47.8 (29.2, 62.2) 948.5 (573.0,
1243.0)
81.3 (33.0, 118.2) 81.6 (57.6, 103.2)
1E9  10.0 (8.0, 16.0) 1643.8 (1325.0, 2379.3) 27.6 (24.6, 42.2) 984.0 (715.5,
1534.0)
58.4 (47.5, 84.0) 48.0 (38.4, 108.2)
E24377A
5E8  6.0 (4.0, 9.0) 786.5 (383.9, 1139.0) 11.7 (6.6, 13.5) 556.1 (326.0,
845.0)
27.3 (19.8, 29.7) 29.7 (17.0, 33.2)
5E9 6.0  (4.0, 8.0) 979.0 (479.6, 1183.8) 14.2 (11.6, 22.0) 508.8 (386.0,
771.0)
29.2 (10.4, 41.3) 119.8 (16.5, 119.9)
B7A
1E9  5.0 (4.0, 10.0) 822.0 (587.0, 915.0) 9.4 (7.3, 11.0) 435.0 (382.0,
651.0)
42.1 (41.9, 126.0) 156.0 (144.0,
156.0)
1E10  5.5 (3.0, 7.5) 825.0 (684.5, 998.5) 13.9 (11.0, 15.1) 543.5 (491.0,
809.5)
30.0 (13.6, 50.8) 60.0 (36.0, 132.0)
LSN03-
016011/A
5E8 7.0  (4.0, 10.0) 753.3 (556.2, 1612.5) 50.0 (24.9, 87.4) 556.2 (264.0,
1033.5)
47.3 (25.2, 71.3) 120.3 (96.3, 120.3)
5E9  8.0 (5.0, 10.0) 910 (624.7, 1209.6) 22.6 (17.7, 26.6) 771.2 (519.0,
999.0)
35.6 (15.5, 54.3) 48.3 (24.3, 120.3)
WS0115A
5E8  5.0 (–) 1186.0 (–) 16.7 (–) 1186.0 (–) 10.0 (–) 27.0 (–)
5E9 6.0  (5.0, 7.0) 676.5 (402.0, 951.0) 6.8 (5.1, 8.4) 448.5 (402.0,
495.0)
46.9 (22.2, 71.5) 120.0 (–)
1E10  4.5 (3.5, 5.0) 737.8 (420.5, 927.0) 25.1 (19.6, 26.3) 439.8 (391.1,
624.4)
36.0 (26.0, 53.8) 120.0 (–)
DS26-1  5E8 – – – – – –
the low and high doses of H10407 until the 96 h mark where they
are exceeded by the low dose of H10407. The other dose/strain
combinations show increases in stool volume and count through
the 72–84 h post-inoculation timepoint at which point they tend to
level off. Importantly, there was variability in the median time to
antibiotic treatment (Table 4), although this alone does not account
for the temporal variability in diarrhea output.
Using multivariate models, we found several important predic-
tors of clinical outcomes. The risk of diarrhea, malaise and headache
was variable by ETEC strain. Specifically, when using H10407 as
the reference, subjects receiving the WS0115A strain had a signifi-
cantly decreased risk of diarrhea (Relative Risk {RR} = 0.63, p = 0.03)
and headache (RR = 0.47, p = 0.04). Similarly, the risk of headache
was decreased in subjects receiving either the LSN03-016011/A
(RR = 0.35, p < 0.01) or E24377A (RR = 0.44, p < 0.01) strains and sub-
jects receiving the B7A strain had a borderline significant decreased
risk of malaise (RR = 0.36, p = 0.06). Regardless of strain adminis-
tered, the risk of headache increased with increasing inoculum
dose (RR = 1.23, p = 0.05) and was higher in females than in males
(RR = 1.39, p = 0.07). Being of female gender also increased the risk of
Fig. 3. Volume and number of loose stools over observation period by strain and
dose. Bars: stool count; Lines: stool volume.
reporting nausea (RR = 1.92, p < 0.01) and abdominal pain or cramps
(RR = 1.39, p = 0.07). The risk of nausea was also higher in subjects of
Caucasian race (RR = 1.49, p = 0.04), compared to those of African-
American race. We  found no effect of dose on the risk of any other
outcomes (other than headache) likely due to the narrow range
of relatively high inocula evaluated. In contrast, increasing base-
line LT IgG levels were associated with a decreased risk of diarrhea
(RR = 0.85, p = 0.02). However, this association was  not consistent
when stratified by diarrhea severity (data not shown). There was
no association with baseline LT IgA or any titers to the homologous
colonization factors.
3.2.2. Immunology data
Serologic and ASC responses to LT and homologous colonization
factor were relatively common for all dose/strain combinations.
Overall, baseline serologic titers to LT (IgA GMT: 85, IgG GMT: 10)
were low across all studied dose/strain combinations as were sero-
logic titers to homologous fimbriae (CFA/I: IgA GMT:4, IgG GMT:16;
CS1: IgA GMT:296, IgG GMT:764; CS3: IgA GMT:376, IgG GMT:378;
CS6: IgA GMT:4, IgG GMT:17; CS17: IgA GMT:3, IgG GMT:13; CS19:
IgA GMT: 17, IgG GMT: 31). Neither anti-LT IgA baseline titers
nor anti-CF IgG or IgA appeared to correlate with diarrhea risk
or severity. Similarly, baseline levels of antibody secreting cells
(ASCs) specific to either LT or the homologous CF were low with
only 5 subjects presenting with at least 1 ASC per 106 peripheral
blood mononuclear cells (PBMC). All 5 subjects had diarrhea post-
inoculation (1 severe, 2 moderate and 2 mild) likely reflecting no
association between low level ASCs at baseline and diarrhea risk
following inoculation.
Early antibiotic treatment did not appear to reduce the fre-
quency or magnitude of serologic or ASC responses to LT or
homologous CF with the majority of subjects exhibiting a response
to both antigens (data not shown). Additionally, there was no sig-
nificant association between the time to antibiotic treatment and
maximum LT or CF titers (data not shown). Similarly, the dura-
tion of the subject’s diarrheal episode had no significant impact on
resultant maximum LT or CF titers (data not shown).
4. Discussion
A  systematic review of 27 studies on 11 ETEC strains highlights
variability in inoculum preparation and administration as well as
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Fig. 4. Similarities and discrepancies between ETEC-associated clinical symptoms from adults with travelers’ diarrhea and participants in experimental ETEC infection
studies. Each of the letters reference a specific epidemiologic study of adult travelers’ diarrhea. References are as follows: B = [23], F = [22], M = [24], P = [28], S = [25]. The
represents the average point estimate with 95% confidence intervals calculated from the individual patient-level data.
differences in clinical and immunological outcomes across stud-
ies. We were able to calculate general estimates of diarrhea attack
rates for the 3 most utilized strains, B7A, E24377A and H10407;
however, report variability complicated calculations of aggregate
outcome measures for given strains and/or doses. Furthermore,
utilization of individual patient-level data enabled summative
estimates of disease severity parameters and identification of
strain and host-specific factors associated with specific clinical
outcomes.
4.1. Report variability
A total of 27 different studies of ETEC experimental infection
have been performed to date, the majority of which are available
in the peer-reviewed literature. Of the published studies, variabil-
ity existed in data reported and methods of analysis. Specifically,
while all authors provided information on the number of subjects
that met  the primary diarrhea outcome, very few provided detailed
information on the disease course of those subjects. Additional
information on other ETEC-associated symptoms, including their
severity, requirements for intravenous therapy, time from antibi-
otic treatment to microbial cure, and duration of ETEC-associated
symptoms after antibiotic treatment would guide future protocol
and informed consent development. Additionally, specific sum-
mary measures describing the diarrheal episode such as total
stool volume, number of stools passed and time to event infor-
mation would be of equal importance to increase comparability of
data across different strains and doses. In an effort to standardize
reporting and identify minimum data elements from experimental
infection studies, we recommend a consortium be formed to define
critical data elements similar to what has been done with travelers’
diarrhea treatment trials [20].
4.2. Similarity to natural infections
To date, the results of experimental infection models have
shown a great diversity in disease severity across a range of doses
for a given strain, and among ETEC strains at similar doses. Some
have argued that the most rigorously studied strains induce ETEC
disease inconsistent with that observed in natural settings such
as among naive travelers to an endemic region [21]. While there
are numerous epidemiological studies on traveler’s diarrhea, few
have reported ETEC-specific outcomes and clinical presentation in
a naive, adult population. As shown in Fig. 4, the estimates from
those studies can be directly compared to estimates obtained from
human challenge studies described here.
Most recently, Frech et al. described the results of a placebo-
controlled clinical trial evaluating an LT skin patch vaccine in
travelers to Guatemala or Mexico [22]. Placebo recipients with
ETEC-attributable disease experienced a median of 2.2 days of diar-
rhea and a median of 10.5 (range: 5–30) loose stools. A slightly
longer duration (median of 6 days) and slightly lower total num-
ber of loose stools (median of 6 loose stools) was reported by
Bolin et al. in a similar population traveling to these 2 countries
[23]. Among Finnish travelers to Morocco, Matilla et al. reported a
median diarrhea duration of 3.1 days and a total output of 7.5 loose
stools with onset occurring approximately 6 days after arrival into
the country [24]. In addition to diarrhea, subjects with ETEC also
reported abdominal pain (71%), nausea/vomiting (18%), fever (18%),
headaches (24%) and myalgias (19%). The rates of these concurrent
ETEC-related symptoms are similar to those reported by Sanders
et al. in U.S. military personnel involved in a training exercise in
Thailand [25].
Although in these studies ETEC has tended to be classified as a
more mild disease, it can clearly present as a more severe dehy-
drating illness requiring intravenous rehydration [26]. The drivers
of disease severity are largely unknown; though likely represent an
interplay between host and pathogen factors. One factor that has
inconsistently shown a significant association with increased dis-
ease severity is ST production either alone or in combination with
LT [27,28].  This is consistent with what has been observed in exper-
imental infection studies, although the data for LT-only producing
strains are limited. To date, only 4 LT-only strains have been admin-
istered: LSN03-016011/A, DS26-1, E2528-C1, TD255-C4 (Table 2).
While doses have ranged from 5E8 to 1E10, diarrhea attack rates
have been relatively low across the dose/strain combinations with
relatively infrequent and less severe associated symptoms. How-
ever, this clearly does not explain all the variation observed within
the experimental infection studies as strains producing ST only
and LT and ST in combination have resulted in a continuum (i.e.,
from mild to severe) of clinical symptoms at various inoculum
levels.
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Table  5
Products assessed using the ETEC human challenge model.
Reference Year Author Product (route) Strain Dose (cfu) Result
[64] 1981 Clements Lactobacillus
acidophilus
TD225-C4 1 × 1010 No protection against diarrhea
Lactobacillus
bulgaricus (oral)
214-4 1 × 108 No protection against diarrhea
H10407 1 × 108 No protection against diarrhea
B7A 1 × 108 No protection against diarrhea
B7A 1 × 1010 No protection against diarrhea
[65]  1982 Levine Type 1 somatic pili
(intramuscular)
H10407 5 × 108 Significant protection from
diarrhea
H10407 5 × 108 Nonsignificant decrease
(37.5%) in diarrhea attack rates
compared to controls
H10407 1 × 107 No protection against diarrhea
B7A 1 × 1010 No protection against diarrhea
[14]  1983 Graham Bismuth subsalicylate
(oral)
H10407 1 × 108 Significant protection from
diarrhea
[66]  1984 Evans CFA/I and CFA/II (oral) H10407 4 × 108 No protection against diarrhea
H1765 4 × 108 No protection against diarrhea
CFA/I (subcutaneous
prime followed by two
oral doses 1 week
apart)
H10407 4 × 108 25% lower diarrhea attack rate
compared to subjects receiving
oral vaccination only
[16,17] 1986 Levine E1392-75-2A: live
attenuated strain
expressing CS1 and CS3
(oral)
E24377A 5 × 108 Significant protection from
diarrhea
[30]  1988 Evans Killed whole cell strain
H10407 (oral)
H10407 5 × 109 Significant protection from
diarrhea
B2C 3 × 108 Diarrhea attack rate of 25% (no
comparable placebo
comparator
CFA/I; O63:H- Not reported Diarrhea attack rate of 25% (no
comparable placebo
comparator)
[31] 1988 Evans Killed whole cell strain
H10407 (oral)
H10407 5 × 109 Significant protection from
diarrhea
[40]  1988 Tacket Bovine milk IgG against
common ETEC O
serogroups (oral)
H10407 1.2 × 109 Significant protection
[68] 1994 Tacket CS1 and CS3
encapsulated in
biodegradable
microspheres
(intestinal tube)
E24377A 3 × 109 Nonsignificant decrease
(30.0%) in diarrhea attack rates
compared to controls
[41]  1998 Freedman Bovine milk IgG against
CFA/I (oral)
H10407 1 × 109 Significant protection from
diarrhea
[69] 1999 Tacket Enteric-coated
capsules containing
bovine milk IgG against
CFA/I, CS3 and CS6
E24377A 1 × 108 Significant protection from
diarrhea
[21]  2007 McKenzie LT (skin patch) E24377A 6 × 108 No protection against
moderate to severe diarrhea;
amelioration of disease
[71]  2008 McKenzie PTL-003: live
attenuated strain
expressing CS1 and CS3
(oral)
E24377A 3 × 109 No protection against
moderate to severe diarrhea
4.3. Model utility
It  can be argued that the ETEC volunteer challenge model is an
overly rigorous and artificial method for assessing preliminary effi-
cacy of ETEC vaccine candidates. As reported by McKenzie et al., an
LT skin patch vaccine failed to protect against diarrhea in an exper-
imental infection study with the strain E34277A, although there
were trends toward a less severe illness in the vaccinated subjects
[21]. However, when that vaccine (with minor modifications in the
administration) was evaluated in a relatively small logistics field
trial, a statistically significant reduction was observed in the rate of
moderate to severe diarrhea of any cause and in the number of loose
stools and duration of illness among those who developed ETEC-
associated diarrhea [22]. Those data were not corroborated in an
expanded field trial and subsequent development of the ETEC patch
vaccine was  halted [29]. While the results of the expanded efficacy
study have not been released in detail, it would be of interest to
assess the correlation between efficacy effect estimates between
that study and the original vaccination/challenge study.
To date, the only ETEC vaccine that has shown statis-
tically significant protection in vaccination-challenge studies
is the oral, colicin E2 treated, whole-cell vaccine evaluated
by Evans et al. [30,31]. However, lack of additional clinical
development of that vaccine precludes any assessment of the
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utility of the human challenge model to predict field effi-
cacy.
Bismuth subsalicylate has been shown to afford significant
protection (protective efficacy = 76.3%) against ETEC-associated
diarrhea in the experimental infection model [14,15]. These results
correlated well with several field studies evaluating the efficacy of
bismuth subsalicylate against all-cause diarrhea [32]. Specifically,
in field studies of diarrhea in travelers to endemic regions, pro-
phylaxis with bismuth subsalicylate yielded an approximate 65%
efficacy against all-cause diarrhea [33–35].  While bismuth subsali-
cylate prophylaxis is not the same as active vaccination, these data
highlight the potential utility of these models in predicting out-
comes in large scale clinical trials in travelers to ETEC endemic
settings.
Although markedly different than disease prevention, Black
et al. assessed trimethoprim and trimethoprim-sulfamathoxazole
(Bactrim) in the treatment of subjects with experimentally induced
ETEC diarrhea [36]. They saw a significant decrease in the number
of loose stools and in diarrhea duration among those receiving the
study drugs compared to those receiving placebo. This is consistent
with studies of travelers’ diarrhea treatment with these antibiotics
[37–39].
Tacket et al. evaluated the ability of bovine milk antibodies
raised against ETEC expressing CFA/I to confer passive protection
against diarrhea in volunteers challenged with H10407 [40]. This
was followed by a study by Freedman et al. demonstrating sig-
nificant protection utilizing bovine milk antibodies against only
the CFA/I fimbriae [41]. Unfortunately, despite these positive find-
ings, no field studies utilizing either of these formulations have
been conducted precluding a direct comparison between the two
settings.
A listing of the prophylactic products assessed using the ETEC
human challenge model is included in Table 5, and a review of
ETEC vaccine candidates, including those assessed using these
models has been previously reported [42]. It should be noted
that the studies referenced above only compare and contrast
field epidemiological studies with experimental infection stud-
ies in adults. This fails to represent the population with the
highest disease burden, children living in ETEC endemic regions.
This population is not one in which experimental ETEC infec-
tion would be ethically justifiable. This represents a potential
challenge even if the experimental infection model is deemed
an adequate predictor of field efficacy in an adult traveler
population.
4.4. Unique severity with H10407
It has long been recognized that ETEC strain H10407 causes sig-
nificant disease in experimental infection studies. Although other
ETEC strains with similar diarrhea attack rates have been eval-
uated, H10407 appears to induce a more severe diarrhea. For
example, in the study by McKenzie et al. evaluating a bovine
milk IgG product, four of the eleven placebo recipients (36%) had
over 10 diarrheal stools totaling 2.0–6.5 L. This is similar to the
amount of fluid loss seen following an infection with Vibrio cholera
O1 [43]. In addition to the significant diarrheal output, H10407
is associated with more severe concurrent signs and symptoms
with fever and vomiting reported in a relatively high proportion
of subjects compared to volunteers challenged with other ETEC
strains. Efforts are ongoing to evaluate lower inoculum doses of
H10407 [44]. These studies may  identify lower inoculum doses
that retain a high diarrhea attack rate yet result in a lower
frequency of high volume output and less severe concurrent symp-
toms.
A number of proposed virulence factors have been identified
for H10407 including EAST [45], Tia [46,47],  Tib [47], leoA [48],
EatA [49] and EtpA [50]. However, studies to date are unclear as
to the effect each may  play in the pathogenesis observed in experi-
mental human infections and may  not fully explain the differential
effect seen with this particular strain compared to other ETEC chal-
lenge strains administered to date. The human challenge model
could be used to compare the disease severity produced by H10407
compared to isogenic mutants lacking one or more of these genes.
Additionally, this model could be utilized to evaluate host genomics
and differences in innate and adaptive immune responses and
effects on the host’s microbiome.
4.5. Ethics
All clinical trials must weigh the ethical dilemmas involved
with putting human subjects at risk against the potential bene-
fit of a future drug, vaccine or other product designed to treat or
prevent disease. This is no different in experimental ETEC infec-
tions, and in fact may  be more difficult to appropriately balance
the risk-benefit ratio. The ethical framework developed by Miller
and Grady offers a structure by which to evaluate experimental
infection studies and can serve as a guide for future ETEC infection
research [51]. They highlight seven ethical issues that should be
used to evaluate proposed studies, the most pertinent of which is
“Risk”. While ETEC-associated diarrhea in adults has generally been
thought of as a relatively mild, self-limited disease, recent literature
has highlighted a potential association with post-infectious seque-
lae. Two separate meta-analyses have shown a 7-fold increase in
the risk of developing post-infectious irritable bowel syndrome
(PI-IBS), following an episode of acute infectious gastroenteritis
(IGE), of which ETEC is a common cause [52,53] and two  stud-
ies have found this association in areas of high ETEC prevalence
[54,55]. Although the pathogen-specific attributable risk for this
post-infectious sequelae is currently unknown, these data suggest
a new paradigm in the understanding of infectious diarrhea, includ-
ing ETEC, and its impact on long-term health. In addition, a growing
body of literature has shown a similar association between IGE and
inflammatory bowel disease (IBD) [56–58].  Although unlikely to
be identified in post-infection follow-ups due to its generally rare
occurrence, this association highlights the need for further study
of a pathogen that was once thought to cause only a self-limiting
diarrhea.
Based on the relatively high inoculum required to elicit diar-
rhea in a sufficient number of subjects and the inverse association
between diarrhea risk and baseline LT IgG titers, one may  hypoth-
esize that inclusion of serologic screening, as has been utilized for
Campylobacter jejuni challenge model development [59,60],  may
decrease the required inoculum. None of the studies reviewed here
reported serologic screening of potential study participants. How-
ever, several did report an exclusion for subjects with prior travel to
ETEC-endemic regions and/or exclusion for known ETEC exposure.
It is unclear what the added impact of baseline serologic screening
may  have on future utilization of the model.
The experimental human ETEC challenge has proved invaluable
in defining and understanding strain pathogenicity, highlight-
ing strain variability in disease manifestation and increasing our
knowledge of the human immune response. It has also served as an
important tool in the evaluation of vaccines and other experimental
therapies. The information gleaned from these studies should guide
future experimental ETEC challenge studies of existing and novel
ETEC strains. With our expanding understanding of genomics, pro-
teomics and microbiomics, data obtained from human challenge
models may  provide the opportunity to gain a better understand-
ing of pathogenesis, host factors impacting susceptibility as well as
develop more, well-characterized and targeted vaccines and adju-
vants thereby increasing efficacy.
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